Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Annevex Life Sciences fiscal 2025 third quarter conference call. My name is Clint Tomlinson and I will be your host for today's call. At this time all participants are in listen only mode and later we will conduct a question and answer session before or during this session we would like to ask a question. Please use the Q&A box or raise your hand. Please note this conference is being recorded and the call will be available on Annevex's website at .annevex.com later today. With us today is Dr. Christopher Misling, President and Chief Executive Officer and Sondar Bohnush, Principal Financial Officer. Before we begin please note that this conference call the company will make some projections and forward looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SEC and this includes without limitation the company's forms 10K and 10Q which identify specific factors that may cause actual results or events to differ material from those described in these forward looking statements. These factors may include without limitation risks inherent in the development and or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital and maintenance of intellectual property rights. With that I'd like to turn the call over to Dr. Misling. Thank you, Clint and good morning everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update. Our development of non-invasive targeted upstream compounds continues to advance particularly in...